<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180828</url>
  </required_header>
  <id_info>
    <org_study_id>pkuszh-2014-02</org_study_id>
    <nct_id>NCT02180828</nct_id>
  </id_info>
  <brief_title>Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis</brief_title>
  <official_title>An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is focused to prove that the efficacy and safety of Clotrimazole vaginal tablet vs
      Fluconazole for the treatment of severe vulvovaginal candidiasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is evaluating both the efficacy and safety of the 2 doses of 500 mg
      clotrimazole vaginal tablet administered intravaginally( at day 1 and day 4) v.s 2 doses of
      150 mg fluconazole( at day 1 and day 4) for treatment of severe vulvovaginal candidiasis.The
      number of participants with adverse events as a measure of safety and tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Efficacy 1</measure>
    <time_frame>7-14 days after treatment (=visit 2)</time_frame>
    <description>The clinical cure rates of clotrimazole and fluconazol: Clinical cure was defined as the resolution of symptoms present at baseline with a total severity score of ≤2. Improvement was defined as considerable reduction in the severity of baseline signs and symptoms with a decrease in the total score by ≥50%.Patients not clinically cured or showing improvement were considered clinical failures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic Efficacy 2</measure>
    <time_frame>at days 30-35 follow-up</time_frame>
    <description>The clinical cure rates of clotrimazole and fluconazol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic Efficacy 3</measure>
    <time_frame>at days 7-14 follow-up</time_frame>
    <description>Mycological cure of clotrimazole group and fluconazole group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic Efficacy 4</measure>
    <time_frame>at days30-35 follow-up</time_frame>
    <description>Mycological cure of clotrimazole group and fluconazole group: Mycological cure or failure was referred to as Candida negative or positive,respectively, on Candida culture at follow-up visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events 1</measure>
    <time_frame>at day 7-14 follow up</time_frame>
    <description>Systemic: weak, palpitation, tachycardia, migraine, headache, dizzy, rhinorrhea, numb, dizziness, fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events 2</measure>
    <time_frame>at day 7-14 follow up</time_frame>
    <description>Vulvovaginal pruritus, burning, irritation, and bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events 3</measure>
    <time_frame>at day 7-14 follow up</time_frame>
    <description>Gastrointestinal tract: abdominal pain, diarrhoea, nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events 4</measure>
    <time_frame>at day 7-14 follow up</time_frame>
    <description>Skin sensitivity, urticaria rash, erythematous rash, irritation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Adverse Events</measure>
    <time_frame>at day 7-14 follow up</time_frame>
    <description>Total adverse events(cases)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Candidiasis, Vulvovaginal</condition>
  <arm_group>
    <arm_group_label>Clotrimazole vaginal tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole vaginal tablet</intervention_name>
    <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
    <arm_group_label>Clotrimazole vaginal tablet</arm_group_label>
    <other_name>Canesten</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a
             numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3)
             with a minimum VVC Composite Signs/Symptoms score of 7

          2. Subject completes the informed consent process

          3. Subject agrees to take study medication when scheduled

          4. Subject complies with all clinical trial instructions. Commits to all follow-up visits

        Exclusion Criteria:

          1. had any other sexually transmitted disease or gynaecological abnormality requiring
             treatment

          2. had a disease known to predispose to candidiasis such as diabetes mellitus, or were
             receiving antibiotics or corticosteriods

          3. were pregnant

          4. had used antifungal medication in the week before entry

          5. were expected to menstruate within seven days of the start of treatment

          6. infected more than one candida species
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shangrong Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/myc.12485/epdf</url>
    <description>The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis</description>
  </link>
  <results_reference>
    <citation>Zhou X, Li T, Fan S, Zhu Y, Liu X, Guo X, Liang Y. The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. Mycoses. 2016 Jul;59(7):419-28. doi: 10.1111/myc.12485. Epub 2016 Apr 13.</citation>
    <PMID>27073145</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <results_first_submitted>April 16, 2016</results_first_submitted>
  <results_first_submitted_qc>August 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Prof of Dept of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://onlinelibrary.wiley.com/doi/10.1111/myc.12485/epdf</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://onlinelibrary.wiley.com/doi/10.1111/myc.12485/epdf</doc_url>
      <doc_comment>The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clotrimazole Vaginal Tablet</title>
          <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
        </group>
        <group group_id="P2">
          <title>Fluconazole</title>
          <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clotrimazole Vaginal Tablet</title>
          <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
        </group>
        <group group_id="B2">
          <title>Fluconazole</title>
          <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="6"/>
                    <measurement group_id="B2" value="29" spread="7"/>
                    <measurement group_id="B3" value="29" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Efficacy 1</title>
        <description>The clinical cure rates of clotrimazole and fluconazol: Clinical cure was defined as the resolution of symptoms present at baseline with a total severity score of ≤2. Improvement was defined as considerable reduction in the severity of baseline signs and symptoms with a decrease in the total score by ≥50%.Patients not clinically cured or showing improvement were considered clinical failures.</description>
        <time_frame>7-14 days after treatment (=visit 2)</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy 1</title>
          <description>The clinical cure rates of clotrimazole and fluconazol: Clinical cure was defined as the resolution of symptoms present at baseline with a total severity score of ≤2. Improvement was defined as considerable reduction in the severity of baseline signs and symptoms with a decrease in the total score by ≥50%.Patients not clinically cured or showing improvement were considered clinical failures.</description>
          <population>PPS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Yes</non_inferiority_desc>
            <p_value>0.925</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Efficacy 2</title>
        <description>The clinical cure rates of clotrimazole and fluconazol</description>
        <time_frame>at days 30-35 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy 2</title>
          <description>The clinical cure rates of clotrimazole and fluconazol</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Yes</non_inferiority_desc>
            <p_value>0.298</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Efficacy 3</title>
        <description>Mycological cure of clotrimazole group and fluconazole group</description>
        <time_frame>at days 7-14 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy 3</title>
          <description>Mycological cure of clotrimazole group and fluconazole group</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% power and a two-sided alpha level of 0.05</non_inferiority_desc>
            <p_value>0.147</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Efficacy 4</title>
        <description>Mycological cure of clotrimazole group and fluconazole group: Mycological cure or failure was referred to as Candida negative or positive,respectively, on Candida culture at follow-up visits.</description>
        <time_frame>at days30-35 follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy 4</title>
          <description>Mycological cure of clotrimazole group and fluconazole group: Mycological cure or failure was referred to as Candida negative or positive,respectively, on Candida culture at follow-up visits.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Yes</non_inferiority_desc>
            <p_value>0.147</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events 1</title>
        <description>Systemic: weak, palpitation, tachycardia, migraine, headache, dizzy, rhinorrhea, numb, dizziness, fatigue.</description>
        <time_frame>at day 7-14 follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events 1</title>
          <description>Systemic: weak, palpitation, tachycardia, migraine, headache, dizzy, rhinorrhea, numb, dizziness, fatigue.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events 2</title>
        <description>Vulvovaginal pruritus, burning, irritation, and bleeding</description>
        <time_frame>at day 7-14 follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events 2</title>
          <description>Vulvovaginal pruritus, burning, irritation, and bleeding</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events 3</title>
        <description>Gastrointestinal tract: abdominal pain, diarrhoea, nausea</description>
        <time_frame>at day 7-14 follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events 3</title>
          <description>Gastrointestinal tract: abdominal pain, diarrhoea, nausea</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.658</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events 4</title>
        <description>Skin sensitivity, urticaria rash, erythematous rash, irritation</description>
        <time_frame>at day 7-14 follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events 4</title>
          <description>Skin sensitivity, urticaria rash, erythematous rash, irritation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Adverse Events</title>
        <description>Total adverse events(cases)</description>
        <time_frame>at day 7-14 follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotrimazole Vaginal Tablet</title>
            <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Adverse Events</title>
          <description>Total adverse events(cases)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.274</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>The adverse events of clotrimazole vaginal tablet were mainly local and mild. Most of the adverse events of fluconazole were systemic.</desc>
      <group_list>
        <group group_id="E1">
          <title>Clotrimazole Vaginal Tablet</title>
          <description>2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Clotrimazole vaginal tablet: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)</description>
        </group>
        <group group_id="E2">
          <title>Fluconazole</title>
          <description>2 doses of 150 mg oral Fluconazole (at day1 and day4)
Fluconazole: 2 doses of 150 mg oral Fluconazole (at day1 and day4)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic</sub_title>
                <description>Systemic: weak, palpitation, tachycardia, migraine,headache, dizzy, rhinorrhea, numb, dizziness, fatigue.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal</sub_title>
                <description>Vulvovaginal pruritus, burning, irritation, and bleeding</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shangrong Fan</name_or_title>
      <organization>Peking University</organization>
      <phone>860755-83923333 ext 5502</phone>
      <email>fanshangrong@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

